In development for the treatment of idiopathic pulmonary fibrosis (IPF).

GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells. GRI-0621 has been shown to reduce aminotransferases and other LFTs in patients and improve fibrosis in multiple disease models. GRI is repurposing GRI-0621 as a once-daily oral capsule for the treatment of IPF with the potential to expand into additional fibrotic indications.

Key Highlights:

  • Targets upstream in the inflammatory cascade providing potential for greater efficacy
  • Favorable safety profile demonstrated in prior late stage studies
  • iNKT inhibition demonstrated fibrosis resolution in multiple animal models
  • Extensive IP protection with issued medical use patents and market LOE through 2036

The Need in Idiopathic Pulmonary Fibrosis (IPF)

IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.

  1. Castriotta, R. J. (2010). Workshop on Idiopathic Pulmonary Fibrosis in Older Adults. Chest, 138(3), 693–703;
  2. Sharif, R. (2017). Overview of Idiopathic Pulmonary Fibrosis (IPF) and Evidence-Based Guidelines. Am J Manag Care, 23(11), 176–182

Our Science

Our Pipeline

Our Team